Interference of circulating azathioprine but not methotrexate or sulfasalazine with measurements of interleukin-6 bioactivity

Contains fulltext : 4779.pdf (publisher's version ) (Open Access

An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles.

The tumor necrosis factor (TNF) alpha gene lies within the class III region of the major histocompatibility complex (MHC), telomeric to the class II and centromeric to the class I region. We have recently described the first polymorphism within the human TNF-alpha locus. This is biallelic and lies within the promoter region. Frequency analysis of the TNF-alpha polymorphism, using the polymerase chain reaction and single-stranded conformational polymorphism, in HLA-typed individuals, reveals a very strong association between the uncommon TNF allele and HLA A1, B8, and DR3 alleles. This is the first association between TNF-alpha and other MHC alleles and raises the possibility that the uncommon TNF-alpha allele may contribute to the many autoimmune associations of the A1,B8,DR3 haplotype

Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis

Item does not contain fulltex

Radiographic progression in rheumatoid arthritis: results of 3 comparative trials

Contains fulltext : 20981___.PDF (publisher's version ) (Open Access

Effects of antirheumatic agents on cytokines

Contains fulltext : 23788___.PDF (publisher's version ) (Open Access

Alternative methods for analysis of radiographic damage in a randomized, double blind, parallel group clinical trial comparing hydroxycloroquine and sulfasalazine

Item does not contain fulltext4 p

Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis.

Contains fulltext : 57208.pdf (publisher's version ) (Closed access)OBJECTIVE: To determine cost-effectiveness of folic or folinic acid supplementation in patients with rheumatoid arthritis (RA) who started methotrexate (MTX) treatment. METHODS: An economic evaluation, performed alongside a randomized, double blind, placebo controlled trial with followup of 48 weeks. Patients started MTX with placebo (n = 137), folic acid (n = 133), or folinic acid (n = 141). Outcome measures were drug survival and quality-adjusted life-years (QALY), measured with the EuroQol questionnaire. Both medical and nonmedical costs were analyzed. RESULTS: Drug survival after 48 weeks was 60% for placebo, 81% for folic acid, and 87% for folinic acid. QALY during a 48 week period were 0.55 (95% CI 0.52-0.58) in the placebo group, 0.55 (95% CI 0.52-0.58) in the folic acid group, and 0.58 (95% CI 0.56-0.60) in the folinic acid group. Mean medical costs were 1398 US dollars (placebo), 1409 US dollars (folic acid), and 1776 US dollars (folinic acid). Mean total costs were 3339 US dollars, 3632 US dollars, and 3296 US dollars, respectively. CONCLUSION: In terms of resource deployment, no statistically significant difference was found between the 3 strategies. The preferred strategy consists of folic acid supplementation because of improved drug survival

Evaluating hand surgery in rheumatoid arthritis: short term effect on function and pain, and the relation with patient satisfaction.

Item does not contain fulltext4 p